Jun Zhang
Medical Oncology · Iowa City, IANPI 1902175615
Payments from drug & device makers
Across 803 payments — averaging $9882.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mirati Therapeutics, Inc.$3.4M
- AstraZeneca$2M
- Beigene, Ltd.$857K
- Genentech, Inc.$589K
- Janssen Research & Development, LLC$345K
- AbbVie$198K
- plus $560K from 22 others
Across 2 payments — averaging $7336.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$15K
What the payments were for
- Consulting fees$93,90125%
- Speaking & faculty fees$250,80767%
- Travel & lodging$25,2297%
- Food & beverage$6,6962%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mirati Therapeutics, Inc. | 103 | $3,377,008 |
| AstraZeneca | 77 | $2,009,806 |
| Beigene, Ltd. | 285 | $857,405 |
| Genentech, Inc. | 21 | $588,544 |
| Janssen Research & Development, LLC | 46 | $345,077 |
| AbbVie | 31 | $197,844 |
| Regeneron Healthcare Solutions, Inc. | 112 | $166,324 |
| Novartis | 5 | $160,108 |
| Eli Lilly | 5 | $62,906 |
| Regeneron | 17 | $45,259 |
| Sanofi | 18 | $36,735 |
| Johnson & Johnson | 22 | $29,550 |
| Novocure Inc. | 32 | $22,469 |
| Boehringer Ingelheim | 2 | $9,025 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $8,855 |
| Exelixis Inc. | 1 | $7,376 |
| Fosun Pharma USA Inc. | 2 | $3,220 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,583 |
| Daiichi Sankyo Inc. | 2 | $2,344 |
| Bayer | 1 | $900 |
| Boehringer Ingelheim International GmbH | 1 | $640 |
| Merck | 4 | $539 |
| Amgen | 1 | $366 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 7 | $312 |
| Galvanize Therapeutics, Inc | 1 | $188 |
| Beigene USA, Inc. | 1 | $129 |
| Taiho Oncology, Inc. | 1 | $118 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,935,645 in reported general payments places this provider in the 95th percentile of 47 medical oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 21 | $336,112 |
| GavretoPralsetinib | 11 | $142,091 |
| EliquisApixaban | 13 | $10,219 |
| Dexamethasone | 49 | $579 |
| Ondansetron Hcl | 41 | $460 |
| Prednisone | 33 | $174 |
| Prochlorperazine Maleate | 13 | $165 |
| Oxycodone Hcl | 17 | $154 |
| Potassium Chloride | 20 | $95 |
| Methylprednisolone | 16 | $92 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $2,009,806 | $336,11221 claims |
| PfizerEliquis | $16 | $10,21913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 47 medical oncology providers in Iowa.
Other medical oncology in Iowa City
- Mark BurkardIowa City$2.8M
- Saima SharifIowa City$701K
- Margaret ByrneIowa City$209K
- Fernando Maciel BarbosaIowa City$200K
- Naomi FeiIowa City$165K
- Margarida SilvermanIowa City$97K
- John RiethIowa City$11K
- Gustavo Fernandes Godoy AlmeidaIowa City$2K
- Susan RoederIowa City$47
- Tara GraffClive$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.